Purpose: To evaluate the response and outcome of patients of Hodgkin's disease undergoing different treatment modalities. Materials and Methods: We reviewed clinical records of Hodgkin's disease who received chemotherapy (C/T), radiotherapy (R/T) or combined chemotherapy and radiotherapy (CRT) from 1977 to 1991 in National Taiwan University Hospital ( NTUH). The 5-year survival rate (SR) and 5-year freedom from relapse rate (FFR) in different stages were calculated and classified by different treatment modalities. Result: The overall 5-year survival rate (SR) and 5-year freedom from relapse rate (FFR) were summarized for stage I+Ⅱ, Ⅲ and IV diseases. In stage I+Ⅱ diseases, the SR of CIT, RIT and CRT groups were 50%, 60% and 89%; the FFR were 33%, 100% and 67% respectively. In stage Ⅲdisease, the SR of C/T and CRT groups were 72% and 90%; the FFR were 59% and 90% respectively. In stage IV disease, the SR of C/T and CRT groups were 45% and 38%; the FFR both were 38%. No statistical significance of SR was noted between CT, R/T and CRT groups in different stages. However, the FFR between C/T and R/T groups in the early stage showed statistical significance (p＜O.OS). Patients with histologic subtype of lymphocyte depletion had the worst prognosis than the other 3 histologic subtypes. C/T and CRT groups bad some complications while no complication was seen in the HIT group within the 5-year follow-up. Conclusion: In our study, Hodgkin's disease was potentially curable by using either C/T, R/T, or CRT. For stage Ⅲand IV diseases, no statistical significance was noted by C/T or CRT groups. However, for early stage disease, R/T is a better treatment of choice because R/T group had better FFR and no late complication.
- Hodgkin's disease
- Combined chemotherapy and radiotherapy
- Survival rate
- Freedom from relapse